English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe AAVCOVID vaccine program at Massachusetts Eye and Ear and Massachusetts General Hospital has entered into manufacturing agreements with Viralgen, Aldevron and Catalent in order to support manufacturing of the experimental vaccine for clinical studies in the second half of 2020.
Tag: AAV gene therapy
AAVCOVID Vaccine Program from Mass. Eye and Ear and Mass General Enters Manufacturing Agreement with Gene Therapy Leader AveXis, a Novartis Company
AveXis, will lead the manufacturing efforts of the new AAVCOVID vaccine, utilizing its cutting-edge AAV technology for treatment of rare and life-threatening neurological genetic diseases. AveXis has the option to manufacture the AAV vaccine for additional clinical development, registration and/or commercial activities.
Massachusetts Eye and Ear and Massachusetts General Hospital Advancing Novel Experimental Gene-based COVID-19 Vaccine, AAVCOVID
Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham, today announced progress towards the testing and development of an experimental vaccine called AAVCOVID, a novel gene-based vaccine candidate against SARS-CoV2, the virus that causes COVID-19. The AAVCOVID Vaccine Program is a unique, gene-based vaccine strategy that uses adeno-associated viral (AAV) vector, a clinically established gene transfer technology leveraging the properties of a harmless viral carrier.